Comparing of Kura Oncology Inc. (KURA) and Forward Pharma A/S (NASDAQ:FWP)

Kura Oncology Inc. (NASDAQ:KURA) and Forward Pharma A/S (NASDAQ:FWP), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kura Oncology Inc. 17 0.00 N/A -1.63 0.00
Forward Pharma A/S 1 0.00 N/A -0.18 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Kura Oncology Inc. and Forward Pharma A/S.


Table 2 demonstrates the return on assets, return on equity and net margins of Kura Oncology Inc. and Forward Pharma A/S.

Net Margins Return on Equity Return on Assets
Kura Oncology Inc. 0.00% -40% -35.5%
Forward Pharma A/S 0.00% -2.4% -2%

Risk & Volatility

Kura Oncology Inc. is 150.00% more volatile than S&P 500 because the company has a beta of 2.5. In other hand, Forward Pharma A/S has beta of 2.37 which is 137.00% more volatile than S&P 500.


The Current Ratio of Kura Oncology Inc. is 13.8 while its Quick Ratio stands at 13.8. The Current Ratio of rival Forward Pharma A/S is 74.5 and its Quick Ratio is has 74.5. Forward Pharma A/S is better equipped to clear short and long-term obligations than Kura Oncology Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for Kura Oncology Inc. and Forward Pharma A/S.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kura Oncology Inc. 0 0 1 3.00
Forward Pharma A/S 0 0 0 0.00

Kura Oncology Inc. has a 37.24% upside potential and a consensus target price of $22.

Institutional and Insider Ownership

Kura Oncology Inc. and Forward Pharma A/S has shares held by institutional investors as follows: 70.8% and 20.6%. Kura Oncology Inc.’s share held by insiders are 0.8%.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kura Oncology Inc. -2.3% -4.59% 28.84% 22.41% -2.45% 36.18%
Forward Pharma A/S -2.25% -2.41% -20.41% -13.21% -66.91% 17.95%

For the past year Kura Oncology Inc. was more bullish than Forward Pharma A/S.


Forward Pharma A/S beats Kura Oncology Inc. on 4 of the 7 factors.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The companyÂ’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also develops KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.